Financial StabilityBioAge ended the first quarter with $335.1 million in cash, and the company's balance sheet is expected to fund operations through at least 2029.
Pipeline ProgressBGE-102 continues to advance towards Phase 1 SAD data, indicating progress in the company's pipeline.
Strategic CollaborationsBioAge is involved in multiple discovery collaborations with major companies like Novartis and Lilly, aiming to identify and validate novel targets of aging and exercise.